Moreover, as β-catenin has the ability to enhance androgen receptor (AR) function in prostate cancer [43], the obvious therapeutic goal to abrogate potential oncogenic AR/β-catenin interactions can be easily achieved through the chemopreventive properties of 4HPR also in hormone responsive cells. The gene discussed is AR; the disease is prostate cancer.